| 货号 | 19115-1mg |
| 描述 | Cyclin-dependent kinases (CDKs) are key regulators of cell cycle progression and are therefore promising targets for cancer therapy.1 Purvalanol B is a CDK inhibitor that most potently inhibits Cdk2/cyclin A, Cdk2/cyclin E, Cdk5/p35, and Cdk2/cyclin B (IC50s = 6, 9, 6, and 6 nM, respectively).2 It is inactive against Cdk4/cyclin D1 as well as several other protein kinases. Purvalanol B is a 2,6,9-trisubstituted purine that, at micromolar doses, inhibits the growth of parasites, including Plasmodium.3,4 |
| 别名 | NG 95; |
| 供应商 | Cayman |
| 应用文献 | |
| 1.Bettayeb, K.,Baunbaek, D.,Delehouze, C., et al. CDK inhibitors roscovitine and CR8 trigger Mcl-I down-regulation and apoptotic cell death in neuroblastoma cells. Genes Cancer 1(4), 369-380 (2010). 2.Gray, N.S.,Wodicka, L.,Thunnissen, A.M.W.H., et al. Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors. Science 281, 533-538 (1998). 3.Knockaert, M.,Gray, N.,Damiens, E., et al. Intracellular targets of cyclin-dependent kinase inhibitors: Identification by affinity chromatography using immobilised inhibitors. Chemistry & Biology 7(6), 411-422 (2000). 4.Bullard, K.M.,Broccardo, C., and Keenan, S.M. Effects of cyclin-dependent kinase inhibitor Purvalanol B application on protein expression and developmental progression in intra-erythrocytic Plasmodium falciparum parasites. Malar.J. 14, (2015). | |
| 运输条件 | Wet ice in continental US; may vary elsewhere |
| 存放说明 | -20 |
| 纯度 | ≥95% |
| 计算分子量 | 432.9 |
| 分子式 | C20H25ClN6O3 |
| CAS号 | 212844-54-7 |
| 稳定性 | ≥ 2 years |
| 本官网所有报价均为常温或者蓝冰运输价格，如有产品需要干冰运输，需另外加收干冰运输费。 |